113 results
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
) There is no claim, action, suit, audit, assessment, arbitration or inquiry, or any proceeding or, to the Stockholder’s knowledge, investigation, by or before
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
upon, among other things, our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration … trials includes evaluation and assessment by an institutional biosafety committee (“IBC”), a local institutional committee that reviews and oversees
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event), prepare a supplement or amendment
8-K
EX-10.2
w67uonoyjp nrt
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
0ux8zxdi3shjvzmgs
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
h9fj1ge0uqhi6 zjq
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
dtoa9k25
8 Dec 23
Prospectus supplement
4:06pm